Edwards Lifesciences Corp. this week secured FDA approval for Triformis Resilia, which the company says is the first and only surgical valve designed specifically for patients with tricuspid valve disease.
The Irvine-based medical device maker received premarket approval for the valve last year and is planning for a U.S. launch in the second half of this year.
Shares in Edwards fell 1% today to $86.65 and a $49.8 billion market cap (NYSE: EW).
